Meningococcal Vaccine Market Size Worth $4.5 billion by 2026

Published Date: 5-Feb-2021

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

According to a new report Global Meningococcal Vaccine Market, published by KBV research, The Global Meningococcal Vaccine Market size is expected to reach $4.5 billion by 2026, rising at a market growth of 8.5% CAGR during the forecast period.

Bexsero had the largest revenue share of the market in 2019 owing to lower cost, fewer doctor visits, and reduced doses. For example, in 2018, the European Commission permitted a reduced dose of Bexsero that target serogroup B in infants. Moreover, according to a study published in the New England Journal of Medicine in January 2020, Bexsero had a positive impact on infants who were immunized under the National Immunisation Programme.

The Quadrivalent market dominated the Global Meningococcal Vaccine Market by Type in 2019, growing at a CAGR of 8.2 % during the forecast period. The Bivalent market would showcase a CAGR of 8.7% during (2020 - 2026).

The North America market dominated the Global Meningococcal Vaccine Market by Region in 2019. In the Asia Pacific, the market is likely to grow at a significant rate during the forecasted period. The growth is accredited to the increasing pediatric population and favorable and supportive initiatives by the government to fight the rising occurrence of the disease in this region. The Europe market is estimated to grow at a CAGR of 8% during (2020 - 2026).

Full Report: https://www.kbvresearch.com/meningococcal-vaccine-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)

Global Meningococcal Vaccine Market Segmentation

By Brand

  • Bexsero
  • Trumenba
  • Nimenrix
  • Menactra
  • Menveo
  • Other Brands

By Type

  • Bivalent
  • Quadrivalent
  • Other Types

By Age Group

  • Infants (0 to 2 years)
  • Children (2 years & above)

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Sanofi S.A.
  • Walvax Biotechnology Co., Ltd.
  • Bio-Manguinhos (Oswaldo Cruz Foundation)
  • Bio-Med Pvt. Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • Incepta Pharmaceuticals Ltd.
  • Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Meningococcal Vaccine Market Related Reports:

North America Market

Europe Market

Asia Pacific Market

LAMEA Market

Request a Free Sample Copy


Why Choose Us

  • 24/7 Research support
    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Information security
    Your personal and confidential information is safe and secure.